| Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trial NA Rizvi, BC Cho, N Reinmuth, KH Lee, A Luft, MJ Ahn, ... JAMA oncology 6 (5), 661-674, 2020 | 566 | 2020 |
| Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway BW Higgs, Z Liu, B White, W Zhu, WI White, C Morehouse, P Brohawn, ... Annals of the rheumatic diseases 70 (11), 2029-2036, 2011 | 435 | 2011 |
| Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ... Cell 183 (3), 818-834. e13, 2020 | 393 | 2020 |
| Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery SIS Mosely, JE Prime, RCA Sainson, JO Koopmann, DYQ Wang, ... Cancer immunology research 5 (1), 29-41, 2017 | 384 | 2017 |
| Type I interferon: potential therapeutic target for psoriasis? Y Yao, L Richman, C Morehouse, M de los Reyes, BW Higgs, A Boutrin, ... PloS one 3 (7), e2737, 2008 | 357 | 2008 |
| Neutralization of interferon‐α/β–inducible genes and downstream effect in a phase I trial of an anti–interferon‐α monoclonal antibody in systemic lupus erythematosus Y Yao, L Richman, BW Higgs, CA Morehouse, M De Los Reyes, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2009 | 349 | 2009 |
| Sifalimumab, a human anti–interferon‐α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose‐escalation study M Petri, DJ Wallace, A Spindler, V Chindalore, K Kalunian, E Mysler, ... Arthritis & Rheumatism 65 (4), 1011-1021, 2013 | 277 | 2013 |
| Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade QU Zhang, J Luo, S Wu, H Si, C Gao, W Xu, SE Abdullah, BW Higgs, ... Cancer discovery 10 (12), 1842-1853, 2020 | 253 | 2020 |
| Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab R Raja, M Kuziora, PZ Brohawn, BW Higgs, A Gupta, PA Dennis, ... Clinical Cancer Research 24 (24), 6212-6222, 2018 | 226 | 2018 |
| Interferon gamma messenger RNA Signature in tumor biopsies predicts outcomes in patients with non–small cell lung carcinoma or urothelial cancer treated with durvalumab BW Higgs, CA Morehouse, K Streicher, PZ Brohawn, F Pilataxi, A Gupta, ... Clinical Cancer Research 24 (16), 3857-3866, 2018 | 194 | 2018 |
| Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases D Wong, B Kea, R Pesich, BW Higgs, W Zhu, P Brown, Y Yao, ... PloS one 7 (1), e29161, 2012 | 190 | 2012 |
| Interferon‐stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy M Salajegheh, SW Kong, JL Pinkus, RJ Walsh, A Liao, R Nazareno, ... Annals of neurology 67 (1), 53-63, 2010 | 189 | 2010 |
| A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and … BW Higgs, W Zhu, C Morehouse, WI White, P Brohawn, X Guo, ... Annals of the rheumatic diseases 73 (1), 256-262, 2014 | 183 | 2014 |
| Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer L Jiang, J Huang, BW Higgs, Z Hu, Z Xiao, X Yao, S Conley, H Zhong, ... PLoS genetics 12 (4), e1005895, 2016 | 180 | 2016 |
| Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo T Karn, C Denkert, KE Weber, U Holtrich, C Hanusch, BV Sinn, BW Higgs, ... Annals of Oncology 31 (9), 1216-1222, 2020 | 175 | 2020 |
| A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth KL Streicher, W Zhu, KP Lehmann, RW Georgantas, CA Morehouse, ... Oncogene 31 (12), 1558-1570, 2012 | 166 | 2012 |
| Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies RW Georgantas, K Streicher, SA Greenberg, LM Greenlees, W Zhu, ... Arthritis & rheumatology 66 (4), 1022-1033, 2014 | 157 | 2014 |
| Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus Y Yao, BW Higgs, C Morehouse, M de Los Reyes, W Trigona, P Brohawn, ... Human genomics and proteomics: HGP 2009, 2009 | 157 | 2009 |
| Relationship between disease activity and type 1 interferon-and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis SA Greenberg, BW Higgs, C Morehouse, RJ Walsh, S Won Kong, ... Genes & Immunity 13 (3), 207-213, 2012 | 152 | 2012 |
| The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity S Gautam, J Fioravanti, W Zhu, JB Le Gall, P Brohawn, NE Lacey, J Hu, ... Nature immunology 20 (3), 337-349, 2019 | 146 | 2019 |
